Diabetes is a common disease characterized by high level of blood sugar, which is the result of malfunctioning of the pancreas. Diabetic nephropathy is an illness of the kidney glomerulus. Diabetic nephropathy disease is one of the most significant problems leading to morbidity and mortality for diabetic patients. This disease is primarily triggered by microalbuminuria, where the presence of albumin in the urine, in a single day, increases over 300 milligrams. Hypertension, proteinuria, and imbalanced glomerular filtration rate also cause diabetic nephropathy. The imbalanced glomerular filtration rate increases the number of waste products in the blood, and further increases the protein levels in the urine.
Increasing Drug Discovery Investments to Boost Global Diabetic Nephropathy Market
Some of the major symptoms of diabetic nephropathy in the later stages are high blood pressure, increased albumin secretion in urine, swelling in the ankle and legs, serum creatinine, high level of blood urea nitrogen, itching, anemia, nausea, vomiting, and morning weakness. Diabetic nephropathy market can be treated by using disease modifying therapies that administer angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers (ARBs). Angiotensin-converting enzyme (ACE) inhibitors such as captopril, lisinopril, enalapril, and ramipril help lowering the protein content in the urine. ACE and ARBs inhibitors together provide greater protection to the kidneys than what they individually can. Irbensartan, losartan, and candesartan are the major angiotensin II receptors blockers.
The increasing prevalence of obesity and diabetes, the increasing investments in research and development activities in drug discovery and the rising awareness about kidney and diabetes-related disorders are the major factors expected to propel the global diabetic nephropathy market in the years to come. Stringent government rules and regulations, longer approval time for medicines, and lack of therapeutic management for diabetic nephropathy are some of the factors expected to hamper the growth of the global diabetic nephropathy market in the near future. However, the increasing use of combination therapies will contribute towards the growth of the global diabetic nephropathy market in the next few years.
Asia to Lead Global Diabetic Nephropathy Market by 2020
The global diabetic nephropathy market is expected to progress from US$2,262.2 mn in 2014 to US$3,145.9 mn by 2020, expanding at a 5.60% CAGR during the period between 2014 and 2020. The global diabetic nephropathy market is segmented on the basis of mode of treatment and region. The global diabetic nephropathy market, by region, is segmented into Asia, North America, Europe, and Rest of the World. Currently, the global diabetic nephropathy market is dominated by North America, followed by Europe. However, Asia is expected to expand at the fastest CAGR in the near future due to the rising incidence of kidney diseases.
By mode of treatment, the global diabetic nephropathy market is classified into DMT. DMT is sub-segmented into ACE inhibitors, renin inhibitors, ARBs, diuretics, connective tissue growth factor (CTGF) inhibitors, calcium channel blockers (CCBs), antioxidant inflammation modulators (AIMs), endothelin-A receptor (ETAR), monocyte chemoattractant protein (MCP), and G protein-coupled receptors (GPCRs).
Novartis AG, Pfizer, Inc., Sanofi, Reata Pharmaceuticals, Inc., AbbVie, Inc., Mitsubishi Tanabe Pharma Corporation, Merck & Co., Inc., Abbott Laboratories, Eli Lilly and Company, and Bayer AG are some of the leading players in the global diabetic nephropathy market.
Browse Full Global Diabetic Nephropathy Market Research Report With Complete TOC @ https://www.persistencemarketresearch.com/market-research/diabetic-nephropathy-market.asp